Identification and Treatment of Central Sleep Apnoea: Beyond SERVE-HF
- PMID: 29892478
- PMCID: PMC5971678
- DOI: 10.15420/cfr.2018:9:1
Identification and Treatment of Central Sleep Apnoea: Beyond SERVE-HF
Abstract
Central sleep apnoea (CSA) occurs in a large proportion of HF patients. CSA has clear detrimental effects, resulting in intermittent hypoxia and sympathetic activation, and is associated with significant morbidity and mortality. Treatment options are limited following the results of a recent trial in which adaptive servo-ventilation resulted in an increase in cardiovascular mortality. Ongoing studies utilising other forms of positive airway pressure may provide additional insight into the results of this trial. A new neurostimulation therapy, phrenic nerve stimulation, has offered a new physiological approach to the treatment of CSA. This therapy has resulted in improvements in the severity of disease and quality of life.
Keywords: Central sleep apnoea; heart failure; hypoxia; phrenic nerve stimulation.
Conflict of interest statement
Disclosure: WA is a consultant to Respicardia (manufacturer of the phrenic nerve stimulation device discussed); RG is Chief Medical Officer of Respicardia; AP has no conflicts to disclose.
Figures
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous